WallStreetZenWallStreetZen

NASDAQ: IRD
Opus Genetics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IRD

Based on 9 analysts offering 12 month price targets for Opus Genetics Inc

Min Forecast
$8.00+138.81%
Avg Forecast
$11.78+251.58%
Max Forecast
$16.00+377.61%

Should I buy or sell IRD stock?

Based on 9 analysts offering ratings for Opus Genetics Inc.

Strong Buy
Strong Buy
5 analysts 55.56%
Buy
4 analysts 44.44%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IRD's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IRD as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -12.86% per year. Learn More

Be the first to know when Wall Street analysts revise their IRD stock forecasts and price targets.

IRD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-07-06
lockedlocked$00.00+00.00%2026-07-06
lockedlocked$00.00+00.00%2026-06-17
lockedlocked$00.00+00.00%2026-06-15
lockedlocked$00.00+00.00%2026-06-04
Leerink Partners
Bottom 13%
13
BuyInitiates Coverage On$10.00+198.51%2026-05-21
Cantor Fitzgerald
Top 30%
71
Strong BuyInitiates Coverage On$15.00+347.76%2026-03-30
Wedbush
Bottom 4%
4
BuyMaintains$10.00+198.51%2026-03-12
Chardan Capital
Top 3%
98
Strong BuyMaintains$11.00+228.36%2026-03-12

1 of 1

Forecast return on equity

Is IRD forecast to generate an efficient return?

Company
-11.35%
Industry
92.14%
Market
172.12%
IRD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IRD forecast to generate an efficient return on assets?

Company
7.79%
Industry
27.1%
IRD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IRD earnings per share forecast

What is IRD's earnings per share in the next 3 years based on estimates from 19 analysts?

Avg 1 year Forecast
-$1.08
Avg 2 year Forecast
-$0.77
Avg 3 year Forecast
-$0.48

IRD revenue forecast

What is IRD's revenue in the next 3 years based on estimates from 19 analysts?

Avg 1 year Forecast
$13.7M+14.62%
Avg 2 year Forecast
$14.5M+20.83%
Avg 3 year Forecast
$77.7M+548.18%
IRD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IRD revenue growth forecast

How is IRD forecast to perform vs Biotechnology companies and vs the US market?

Company
76.14%
Industry
35.07%
Market
13.9%
IRD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IRD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IRD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IRD$3.35$11.78+251.58%Strong Buy
ALXO$2.02$4.33+114.50%Strong Buy
ELDN$3.57$12.00+236.13%Strong Buy
BCYC$3.95$15.60+294.94%Buy
IMRX$4.36$19.00+335.78%Strong Buy
View Top Biotech Stocks

Opus Genetics Stock Forecast FAQ

Is Opus Genetics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: IRD) stock is to Strong Buy IRD stock.

Out of 9 analysts, 5 (55.56%) are recommending IRD as a Strong Buy, 4 (44.44%) are recommending IRD as a Buy, 0 (0%) are recommending IRD as a Hold, 0 (0%) are recommending IRD as a Sell, and 0 (0%) are recommending IRD as a Strong Sell.

If you're new to stock investing, here's how to buy Opus Genetics stock.

What is IRD's earnings growth forecast for 2026-2028?

(NASDAQ: IRD) Opus Genetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.78%.

Opus Genetics's earnings in 2026 is -$106,932,000.On average, 19 Wall Street analysts forecast IRD's earnings for 2026 to be -$88,167,648, with the lowest IRD earnings forecast at -$104,495,593, and the highest IRD earnings forecast at -$17,093,063. On average, 18 Wall Street analysts forecast IRD's earnings for 2027 to be -$62,316,425, with the lowest IRD earnings forecast at -$98,911,859, and the highest IRD earnings forecast at -$35,895,433.

In 2028, IRD is forecast to generate -$38,768,695 in earnings, with the lowest earnings forecast at -$74,981,571 and the highest earnings forecast at $111,959,564.

What is IRD's revenue growth forecast for 2026-2028?

(NASDAQ: IRD) Opus Genetics's forecast annual revenue growth rate of 76.14% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.9%.

Opus Genetics's revenue in 2026 is $11,983,000.On average, 19 Wall Street analysts forecast IRD's revenue for 2026 to be $1,117,967,728, with the lowest IRD revenue forecast at $0, and the highest IRD revenue forecast at $2,331,493,819. On average, 18 Wall Street analysts forecast IRD's revenue for 2027 to be $1,178,526,009, with the lowest IRD revenue forecast at $0, and the highest IRD revenue forecast at $2,841,355,475.

In 2028, IRD is forecast to generate $6,322,072,910 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $55,937,456,267.

What is IRD's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IRD) forecast ROA is 7.79%, which is lower than the forecast US Biotechnology industry average of 27.1%.

What is IRD's Price Target?

According to 9 Wall Street analysts that have issued a 1 year IRD price target, the average IRD price target is $11.78, with the highest IRD stock price forecast at $16.00 and the lowest IRD stock price forecast at $8.00.

On average, Wall Street analysts predict that Opus Genetics's share price could reach $11.78 by Jul 6, 2027. The average Opus Genetics stock price prediction forecasts a potential upside of 251.58% from the current IRD share price of $3.35.

What is IRD's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IRD) Opus Genetics's current Earnings Per Share (EPS) is -$1.33. On average, analysts forecast that IRD's EPS will be -$1.08 for 2026, with the lowest EPS forecast at -$1.28, and the highest EPS forecast at -$0.21. On average, analysts forecast that IRD's EPS will be -$0.77 for 2027, with the lowest EPS forecast at -$1.22, and the highest EPS forecast at -$0.44. In 2028, IRD's EPS is forecast to hit -$0.48 (min: -$0.92, max: $1.38).

What is IRD's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IRD) forecast ROE is -11.35%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.